# Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

> **NCT04225260** · PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 902 (actual)

## Conditions studied

- Glabellar Lines
- Lateral Canthal Lines

## Interventions

- **BIOLOGICAL:** botulinum toxin neuromodulator

## Key facts

- **NCT ID:** NCT04225260
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-27
- **Primary completion:** 2021-04-12
- **Final completion:** 2021-05-21
- **Target enrollment:** 902 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04225260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04225260, "Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04225260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*